Skip to main content
. 2018 May 17;103(9):1493–1501. doi: 10.3324/haematol.2017.186700

Figure 3.

Figure 3.

Combination of parthenolide (PTL) with sulfasalazine (SSZ) overcomes protective effects of mesenchymal stem cells (MSC). (A) Viability of acute lymphoblastic leukemia (ALL) samples (patients 2, 5, 6, 9, and 10) treated with PTL (10 μM), SSZ (300 μM) or a combination of both agents for 24 hours (h) with or without MSC. (B) Viability of samples (patients 1, 2, 5, 6, and 10) following 24-h exposure to PTL (10 μM) or a combination of PTL with SSZ (300 μM) separated from MSC by transwell inserts. Symbols represent the average viability in replicate samples. Each symbol represents an individual patient. Lines represent median and interquartile range. (C) Thiol concentration in media following incubation with MSC with or without SSZ treatment (n=4). Data represent mean±Standard Deviation. Results were analyzed by one-way ANOVA (A) or paired t-test (B and C). *P≤0.05, **P≤0.01.